Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Cognition Therapeutics, Inc.

< Previous 1 2 3 Next >
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Closing of Public Offering
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Pricing of Public Offering
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.